University of Southern California
USC Norris Comprehensive Cancer Center

Not logged in...

If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 0C-19-7

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Yan Ning, D.M., Cristina De Leon, Coordinator, Chi Nguyen, Coordinator, Leila Andres, Coordinator, Nicole Jensen, Coordinator, Edwin Smura, Coordinator, Mary Ordaz, D.M., Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Taison Tran, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Niranjan Bhatt, D.M., Sodech Kim, Coordinator, Akshay Bhavsar, Coordinator, Atessa Kiani, Coordinator, Alda Inveiss, Coordinator, Lauren Wagner, Coordinator, Negeen Izadian, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.